Latest Advances in Lung Cancer Research

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Recent studies confirm genomic testing for NSCLC enhances treatment choices and survival, advocating for its standardization in clinical practice.

A novel nanoparticle vaccine halts lung cancer spread in mice by training the immune system to attack tumor cells, showing promise for post-surgery cancer prevention.

Johnson & Johnson’s Rybrevant shows comparable efficacy to AstraZeneca’s Tagrisso in advanced NSCLC, suggesting potential as an initial treatment option.

Experimental gene therapy drug HPN328 is being tested with Tecentriq in a trial to enhance immune response against small cell lung cancer.

This study assessed real-world survival among older patients with non–small-cell lung cancer (NSCLC) and brain metastases (BMs) at diagnosis receiving first-line immune checkpoint inhibitors (ICIs) compared with chemotherapy only.

Adding atezolizumab and tiragolumab to chemotherapy may improve survival in extensive stage small cell lung cancer, with further research needed.

Study indicates advanced lung cancer patients may stop immunotherapy after 2 years without impacting survival, requiring further research for confirmation.

Adagrasib shows promise in treating KRAS G12C-mutant NSCLC, with lasting responses and potential as a much-needed targeted therapy.

The FDA granted orphan drug status to Quratusugene ozeplasmid, a promising gene-based therapy for small cell lung cancer, to expedite its development.

New treatments like immunotherapy and targeted therapy are improving post-surgery outcomes for lung cancer, with research ongoing to optimize these methods.